Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
-
-
-
-
-
-
-
Clear Street on Beam Therapeutics Inc (BEAM): muted reaction is 'buying opportunity'
-
-
-
-
-
-
-
Beam Therapeutics Inc (BEAM) PT Raised at Bernstein Following Positive Regulatory Update
-
-
-
-
-
-
-
Beam Therapeutics Inc. (BEAM) spreader of 5K contracts of February 25 and 35 calls as share price down 5.5%
-
-
-
-
-
-
-
Beam Therapeutics receives FDA RMAT designation for BEAM-101 therapy
-
-
-
-
-
-
-
Beam Therapeutics Inc. (BEAM) Granted FDA Orphan Drug Designation for BEAM-101
-
-
-
-
-
-
-
BofA Securities Upgrades Beam Therapeutics Inc (BEAM) to Buy
-
443,825 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

